Commentary Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.33696/Pharmacol.2.017

Artificial Intelligence in Pharma: Positive Trends but More Investment Needed to Drive a Transformation

  • 1Pfizer Inc., New York City, USA
+ Affiliations - Affiliations

Corresponding Author

Peter Henstock, peter.v.henstock@pfizer.com

Received Date: September 09, 2020

Accepted Date: December 15, 2020


Pharmaceutical companies have been actively adopting artificial intelligence (AI) approaches for drug discovery and are starting to focus this technology on clinical trials. The shift from large-scale collaborations to smaller strategic partnerships and recently to internal teams has led to increased headcounts that are being organized to deliver AI across the enterprise. Although the urgency of the COVID-19 could have been a perfect test case for leveraging AI, it drew awareness to the obstacles of data access. As data pipelines have already started to overcome these limitations, the next step to adoption will be to embrace the opportunity for AI to serve as a data-driven complement to scientific processes. Although pharma’s AI investments remain tepid, the improving rates for funding AI initiatives are encouraging. With further investment and the increase in new AI techniques directed at pharma R&D challenges, AI has the potential to be a transforming force across the industry.


Artificial intelligence (AI), Machine learning, Pharma, MLOps, COVID-19

Author Information X